UCSD statin web site expands knowledge of adverse events

15 October 2006

The University of California in San Diego says that a recently-launched web site that allows patients receiving stain-based treatments around the world to report adverse events is playing an important part in bridging the gaps that exist between trial data and clinical experience of this type of medication. The site, which is funded by the Robert Wood Johnson Foundation, is part of a wider National Institutes of Health-funded study being undertaken by Beatrice Golomb, associate professor of medicine, and her team at the University.

The researchers point out that, at this stage, nearly 60% of those who have responded to the survey have reported muscle weakness or fatigue, with about half saying that they had experienced cognitive problems while receiving statin-based therapy for elevated cholesterol.

Prof Golomb, explained that "this line of research is important because many physicians and other experts in heart disease and cholesterol are familiar with the benefits of statins and other cholesterol drugs, but are unfamiliar with the adverse experiences with these drugs that many people have reported - such as effects on muscle pain or weakness, memory and thinking or mood."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight